Advanced in Molecular Mechanisms of Atherosclerosis: From Lipids to Inflammation

Anna Meiliana, Nurrani Mustika Dewi, Andi Wijaya

Abstract


BACKGROUND: Atherosclerosis is a leading cause of vascular disease worldwide. During the past several decades, landmark discoveries in the field of vascular biology have evolved our understanding of the biology of blood vessels and the pathobiology of local and systemic vascular disease states and have led to novel disease-modifying therapies for patients. This review is made to understand the molecular mechanism of atherosclerosis for these future therapies.

CONTENT: Advances in molecular biology and -omics technologies have facilitated in vitro and in vivo studies which revealed that blood vessels regulate their own redox milieu, metabolism, mechanical environment, and phenotype, in part, through complex interactions between cellular components of the blood vessel wall and circulating factors. Dysregulation of these carefully orchestrated homeostatic interactions has also been implicated as the mechanism by which risk factors for cardiopulmonary vascular disease lead to vascular dysfunction, structural remodeling and, ultimately, adverse clinical events.

SUMMARY: Atherosclerosis is a heterogeneous disease, despite a common initiating event of apoB-lipoproteins. Despite of acute thrombotic complications, an adequate resolution response is mounted, where efferocytosis prevents plaque necrosis and a reparative scarring response (the fibrous cap) prevents plaque disruption. However, a small percentage of developing atherosclerotic lesions cannot maintain an adequate resolution response, which leading to the formation of clinically dangerous plaques that can trigger acute lumenal thrombosis and tissue ischemia and infarction.

KEYWORDS: atherosclerosis, oxidative stress, inflammation, efferocytosis, foam cells, thrombosis


Full Text:

PDF

References


Brown MS, Goldstein JL. Heart attacks: gone with the century? Science. 1996; 272: 629, CrossRef.

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016; 133: e38-360, CrossRef.

Libby P, Bornfelt KE, Tall AR. Atherosclerosis. Success, surprises, and future challenges. Circulation. 2016; 116: 531-4, CrossRef.

Gimbrone MA Jr, Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016; 118: 620-36, CrossRef.

Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and brinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012; 126: 2739-48, CrossRef.

Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, et al. Rationale and design of the Cardiovascular In ammation Reduction Trial: a test of the in ammatory hypothesis of atherothrombosis. Am Heart J. 2013; 166: 199-207.e15, CrossRef.

Libby P, Tabas I, Fredman G, Fisher EA. In ammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014; 114: 1867-79, CrossRef.

Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016; 118: 579-85, CrossRef.

Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016; 118: 547-63, CrossRef.

McPherson R, Tybjaerg-Hansen A. Genetics of coronary artery disease. Circ Res. 2016; 118: 564-78, CrossRef.

Feinberg MW, Moore KJ. MicroRNA regulation of atherosclerosis. Circ Res. 2016; 118: 703-20, CrossRef.

Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015; 385: 2264-71, CrossRef.

Paynter NP, Ridker PM, Chasman DI. Are genetic tests for atherosclerosis ready for routine clinical use? Circ Res. 2016; 118: 607-19, CrossRef.

Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016; 118: 535-46, CrossRef.

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380: 581-90, CrossRef.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-97, CrossRef.

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1489-99, CrossRef.

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1500-9, CrossRef.

Hegele RA, Gidding SS, Ginsberg HN, McPherson R, Raal FJ, Rader DJ, et al. Nonstatin low-density lipoprotein—lowering therapy and cardiovascular risk reduction—statement from ATVB Council. Arterioscler Thromb Vasc Biol. 2015; 35: 2269-80, CrossRef.

Williams KJ, Tabas I, Fisher EA. How an artery heals. Circ Res. 2015; 117: 909-13, CrossRef.

Boren J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Urr Opin Lipidol. 2016; 27: 473-83, CrossRef.

Faber M. The human aorta; sulfate-containing polyuronides and the deposition of cholesterol. Arch Pathol. 1949; 48: 342-50, PMID.

Camejo G, Lopez A, Vegas H, Paoli H. The participation of aortic proteins in the formation of complexes between low density lipoproteins and intima media extracts. Atherosclerosis 1975; 21: 77-91, CrossRef.

Iverius PH. The interaction between human plasma lipoproteins and connective tissue glycosaminoglycans. J Biol Chem. 1972; 247: 2607-13, PMID.

Vijayagopal P, Srinivasan SR, Radhakrishnamurthy B, Berenson GS. Interaction of serum lipoproteins and a proteoglycan from bovine aorta. J Biol Chem 1981; 256: 8234 -41, PMID.

Smith EB, Slater RS. Lipids and low density lipoproteins in intima in relation to its morphological characteristics. Ciba Found Symp. 1973; 12: 39-62, CrossRef.

Tamminen M, Mottino G, Qiao JH, Breslow JL, Frank JS. Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 1999; 19: 847-53, CrossRef.

Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 1989; 9: 908-18, CrossRef.

Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol. 2007; 27: 1159-65, CrossRef.

Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995; 15: 551-61, CrossRef.

Williams KJ, Tabas I. Lipoprotein retention--and clues for atheroma regression. Arterioscler Thromb Vasc Biol. 2005; 25: 1536-40, CrossRef.

Borén J, Gustafsson M, Skålén K, Flood C, Innerarity TL. Role of extracellular retention of low density lipoproteins in atherosclerosis. Curr Opin Lipidol. 2000; 11: 451-6, CrossRef.

Borén J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest. 1998; 101: 2658-64, CrossRef.

Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP, Borén J. Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem. 2002; 277: 32228-33, CrossRef.

Sloop CH, Dory L, Roheim PS. Interstitial fluid lipoproteins. J Lipid Res. 1987; 28: 225-37, CrossRef.

Frank PG, Pavlides S, Cheung MWC, Daumer K, Lisanti MP. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol. 2008; 295: C242-8, CrossRef.

Fernández-Hernando C, Yu J, Suárez Y, Rahner C, Dávalos A, Lasunción MA, et al. Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab. 2009; 10: 48-54, CrossRef.

Armstrong SM, Sugiyama MG, Fung KY, Gao Y, Wang C, Levy AS, et al. A novel assay uncovers an unexpected role for SR-BI in LDL transcytosis. Cardiovasc Res. 2015; 108: 268-77, CrossRef.

Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007; 116: 1832-44, CrossRef.

Lao KH, Zeng L, Xu Q. Endothelial and smooth muscle cell transformation in atherosclerosis. Curr Opin Lipidol. 2015; 26: 449-56, CrossRef.

Bostrom MA, Boyanovsky BB, Jordan CT, Wadsworth MP, Taatjes DJ, de Beer FC, et al. Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol. 2007; 27: 600-6, CrossRef.

Oorni K, Kovanen PT. PLA2-V: a real player in atherogenesis. Arterioscler Thromb Vasc Biol. 2007; 27: 445-7, CrossRef.

Gustafsson M, Levin M, Skalen K, Perman J, Friden V, Jirholt P, et al. Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence for a role of lipoprotein lipase. Circ Res. 2007; 101: 777-83, CrossRef.

Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH, Williams KJ, Tabas I. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol. 2008; 28: 1723-30, CrossRef.

Tabas I, Li Y, Brocia RW, Xu SW, Swenson TL, Williams KJ. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J Biol Chem. 1993; 268: 20419-32, PMID.

Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354: 1264-72, CrossRef.

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007; 356: 1304-16, CrossRef.

Williams KJ. What does HDL do? A new mechanism to slow atherogenesis – but a new problem in type 2 diabetes mellitus. Atherosclerosis. 2012; 225: 36-8, CrossRef.

Bihari-Varga M. Influence of serum high density lipoprotein on the low density lipoprotein-aortic glycosaminoglycan interactions. Artery. 1978; 4: 504-9.

Camejo G, Cortez MM, Lopez F, Starosta R, Mosquera B, Socorro L. Factors modulating the interaction of LDL with an arterial lipoprotein complexing proteoglycan: the effect of HDL. Acta Med Scand Suppl. 1980; 642: 159-64, CrossRef.

Umaerus M, Rosengren B, Fagerberg B, Hurt-Camejo E, Camejo G. HDL2 interferes with LDL association with arterial proteoglycans: a possible athero-protective effect. Atherosclerosis. 2012; 225: 115-20, CrossRef.

Sneck M, Nguyen SD, Pihlajamaa T, Yohannes G, Riekkola ML, Milne R, et al. Conformational changes of apoB-100 in SMase-modified LDL mediate formation of large aggregates at acidic pH. J Lipid Res. 2012; 53: 1832-9, CrossRef.

Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest. 1996; 98: 1455-64, CrossRef.

De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2014; 15: 152-60, CrossRef.

Moore KJ, Fisher EA. High-density lipoproteins put out the fire. Cell Metab. 2014; 19: 175-6, CrossRef.

Hewing B, Parathath S, Barrett T, Chung WKK, Astudillo YM, Hamada T, et al. Effects of native and myeloperoxidase-modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2014; 34: 779-89, CrossRef.

Niyonzima N, Samstad EO, Aune MH, Ryan L, Bakke SS, Rokstad AM, et al. Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement activation. J Immunol. 2015; 195: 257-64, CrossRef.

Bursill CA, Castro ML, Beattie DT, Nakhla S, van der Vorst E, Heather AK, et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2010; 30: 1773-8, CrossRef.

Nguyen SD, Javanainen M, Rissanen S, Zhao H, Huusko J, Kivelä AM, et al. Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation. J Lipid Res. 2015; 56: 1206-21, CrossRef.

Chiba T, Chang MY, Wang S, Wight TN, McMillen TS, Oram JF, et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol. 2011; 31: 1326-32, CrossRef.

Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med. 2014; 20: 193-203, CrossRef.

Nicholls S, Ray K, Ballantyne C, Beacham L, Miller D, Ruotolo G, et al. Comparative effects of cholesteryl ester transfer protein inhibition, statin and ezetimibe therapy on atherogenic and protective lipid factors: The accentuate trial. Atherosclerosis. 2016; 252: e237-8, CrossRef.

Williams KJ, Fisher EA. Apolipoprotein-B: the crucial protein of atherogenic lipoproteins. In: Wang H, Patterson C, editors. Atherosclerosis: risks, mechanisms, & therapies. Hoboken: John Wiley & Sons; 2015. p.291-312, CrossRef.

Violi F, Pignatelli P, Basili S. Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation. 2010; 121: 1033-44, CrossRef.

Violi F, Carnevale R, Loffredo L, Pignatelli P, Gallin JI. NADPH Oxidase-2 and atherothrombosis. Insight from Chronic Granulamatous Disease. Arterioscler Thromb Vasc Biol. 2017; 37: 218-25, CrossRef.

Kinscherf R, Claus R, Deigner HP, Nauen O, Gehrke C, Hermetter A, et al. Modified low density lipoprotein delivers substrate for ceramide formation and stimulates the sphingomyelin-ceramide pathway in human macrophages. FEBS Lett. 1997; 405: 55-9, CrossRef.

Mukhin DN, Chao FF, Kruth HS. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler Thromb Vasc Biol. 1995; 15: 1607-15, CrossRef.

Chatterjee SB, Dey S, Shi WY, Thomas K, Hutchins GM. Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues. Glycobiology. 1997; 7: 57-65, CrossRef.

Martin SF, Williams N, Chatterjee S. Lactosylceramide is required in apoptosis induced by N-Smase. Glycoconj J. 2006; 23: 147-57, CrossRef.

Kolmakova A, Kwiterovich P, Virgil D, Alaupovic P, Knight-Gibson C, Martin SF, et al. Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase. Arterioscler Thromb Vasc Biol. 2004; 24: 264-9, CrossRef.

Slowik MR, De Luca LG, Min W, Pober JS. Ceramide is not a signal for tumor necrosis factor-induced gene expression but does cause programmed cell death in human vascular endothelial cells. Circ Res. 1996; 79: 736-47, CrossRef.

Mu H, Wang X, Wang H, Lin P, Yao Q, Chen C. Lactosylceramide promotes cell migration and proliferation through activation of ERK1/2 in human aortic smooth muscle cells. Am J Physiol Heart Circ Physiol. 2009; 297: H400-8, CrossRef.

Edsfeldt A, Duner P, Stahlman M, Mollet IG, Asciutto G, Grufman H, et al. Sphingolipids contribute to human atheroschlerotic plaque inflammation. Arterioscler Thromb Vasc Biol. 2016; 36: 1132-40, CrossRef.

Orsini F, Cremona A, Arosio P, Corsetto PA, Montorfano G, Lascialfari A, et al. Atomic force microscopy imaging of lipid rafts of human breast cancer cells. Biochim Biophys Acta. 2012; 1818: 2943-9, CrossRef.

Shaw AS. Lipid rafts: now you see them, now you don’t. Nat Immunol. 2006; 7: 1139-42, CrossRef.

Pike LJ. Rafts de ned: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res. 2006; 47: 1597-8, CrossRef.

Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997; 387: 569-72, CrossRef.

Anderson RG. The caveolae membrane system. Annu Rev Biochem. 1998; 67: 199-225, CrossRef.

Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol. 1998; 14: 111-36, CrossRef.

Fielding CJ, Fielding PE. Membrane cholesterol and the regulation of signal transduction. Biochem Soc Trans. 2004; 32: 65-9, CrossRef.

Chetty PS, Mayne L, Lund-Katz S, Stranz D, Englander SW, Phillips MC. Helical structure and stability in human apolipoprotein A-I by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci USA. 2009; 106: 19005-10, CrossRef.

Sorci-Thomas M, Thomas MJ. Microdomains, inflammation and atherosclerosis. Circ Res. 2016; 118: 679-91, CrossRef.

Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells. Arterioscler Thromb Vasc Biol. 2015; 35: 280-7, CrossRef.

Subramanian M, Thorp E, Hansson GK, Tabas I. Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest. 2013; 123: 17988, CrossRef.

Ait-Oufella H, Sage AP, Mallat Z, Tedgui A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res. 2014; 114: 1640-60, CrossRef.

Dixon AM, Drake L, Hughes KT, Sargent E, Hunt D, Harton JA, et al. Differential transmembrane domain GXXXG motif pairing impacts major histocompatibility complex (MHC) class II structure. J Biol Chem. 2014; 289: 11695-703, CrossRef.

Anderson HA, Roche PA. MHC class II association with lipid rafts on the antigen presenting cell surface. Biochim Biophys Acta. 2015; 1853: 775-80, CrossRef.

Dubland JA, Francis GA. Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism. Front Cell Dev Biol. 2015; 3: 3, CrossRef.

Jelinek D, Patrick SM, Kitt KN, Chan T, Francis GA, Garver WS. Physiological and coordinate downregulation of the NPC1 and NPC2 genes are associated with the sequestration of LDL-derived cholesterol within endocytic compartments. J Cell Biochem. 2009; 108: 1102-16, CrossRef.

Ghosh S. Early steps in reverse cholesterol transport: cholesteryl ester hydrolase and other hydrolases. Curr Opin Endocrinol Diabetes Obes. 2012; 19: 136-41, CrossRef.

Ghosh S. Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization. Expert Rev Cardiovasc Ther. 2011; 9: 329-40, CrossRef.

Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013; 13: 709-21, CrossRef.

Neufeld EB, O’Brien K, Walts AD, Stonik JA, Malide D, Combs CA, et al. The human ABCG1 transporter mobilizes plasma membrane and late endosomal non-sphingomyelin-associated-cholesterol for efflux and esterification. Biology. 2014; 3: 866-91, CrossRef.

Ito A, Hong C, Rong X, Zhu X, Tarling EJ, Hedde PN, et al. Lxrs link metabolism to in ammation through abca1-dependent regulation of membrane composition and tlr signaling. Elife. 2015; 4: e08009, CrossRef.

Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17: 1410-22, CrossRef.

Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011; 8: 502-12, CrossRef.

Doring Y, Soehnlein O, Weber C. Neutrophil extracellular Traps in atherosclerosis and atherothrombosis. Circ Res. 2017; 120: 736-43, CrossRef.

Döring Y, Drechsler M, Soehnlein O, Weber C. Neutrophils in atherosclerosis: from mice to man. Arterioscler Thromb Vasc Biol. 2015; 35: 288-95, CrossRef.

Moreno JA, Ortega-Gómez A, Delbosc S, Beaufort N, Sorbets E, Louedec L, et al. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur Heart J. 2012; 33: 252-63, CrossRef.

Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res. 2012; 110: 875-88, CrossRef.

Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011; 145: 341-55, CrossRef.

Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015; 278: 483-93, CrossRef.

Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ. 2013; 22: 399-411, CrossRef.

Yahagi K, Kolodgie FD, Otsuka F, Finn AV, Davis HR, Joner M, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2016; 13: 79-98, CrossRef.

Kavuma MM, Rayner KJ, Karunakaran D. The walking dead: macrophage inflammation and death in atherosclerosis. Curr Opin Lipidol 2017; 28: 92-8, CrossRef.

Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. 2000; 20: 1177-8, CrossRef.

Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262-75, CrossRef.

Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M. Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol. 1986; 123: 109-25, PMID.

Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973; 180: 1332-9, CrossRef.

Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med. 1976; 295: 369-77, CrossRef.

Ross R. George Lyman Duff Memorial Lecture. Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis. 1981; 1: 293-311, CrossRef.

Ross R. The pathogenesis of atherosclerosis–an update. N Engl J Med. 1986; 314: 488-500, CrossRef.

Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-9, CrossRef.

Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015; 209: 13-22, CrossRef.

Libby P. In ammation in atherosclerosis. Nature. 2002; 420: 868-74, CrossRef.

Hansson GK. In ammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-95, CrossRef.

Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6: 508-19, CrossRef.

Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996; 94: 2013-20, CrossRef.

Schwartz SM, Galis ZS, Rosenfeld ME, Falk E. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol. 2007; 27: 705-13, CrossRef.

Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005; 46: 937-54, CrossRef.

Libby P. Mechanisms of acute coronary syndromes. N Engl J Med. 2013; 369: 883-4, CrossRef.

Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for super cial erosion. Eur Heart J. 2015; 36: 1394-404, CrossRef.

Gimbrone MA Jr. Vascular Endothelium in Hemostasis & Thrombosis. Edinburgh: Churchill Livingstone; 1986, NLMID.

Gimbrone MA Jr. Vascular endothelium in health & disease. In: Haber E, ed. Molecular Cardiovascular Medicine. New York: Scientific American; 1995. p.49-62, NLMID.

Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003; 91: 7-11, CrossRef.

Gimbrone MAJ. Endothelial Dysfunction and the Pathogenesis of Atherosclerosis, Proceedings of the Fifth International Symposium. New York: Springer-Verlag; 1980.

Gimbrone MA Jr. Vascular endothelium and atherosclerosis. In: Moore S, ed. Vascular Injury and Atherosclerosis. New York: Marcel Dekker; 1981. p.25-52, NLMID.

Gimbrone MA. Atherogenesis: current concepts. In: Schoen FJ, Gimbrone MA Jr, ed. Cardiovascular Pathology: Clincopathologic Correlations and Pathogenic Mechanisms. Baltimore: William & Wilkens; 1995. p.1–11, NLMID.

Atkins GB, Simon DI. Interplay between NF-κB and Kruppel-like factors in vascular in ammation and atherosclerosis: location, location, location. J Am Heart Assoc. 2013; 2: e000290, CrossRef.

Lin Z, Natesan V, Shi H, Dong F, Kawanami D, Mahabeleshwar GH, et al. Kruppel-like factor 2 regulates endothelial barrier function. Arterioscler Thromb Vasc Biol. 2010; 30: 1952-9, CrossRef.

Doddaballapur A, Michalik KM, Manavski Y, Lucas T, Houtkooper RH, You X, et al. Laminar shear stress inhibits endothelial cell metabolism via KLF2-mediated repression of PFKFB3. Arterioscler Thromb Vasc Biol. 2015; 35: 137-45, CrossRef.

Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012; 14: 249-56, CrossRef.

Moyes AJ, Khambata RS, Villar I, Bubb KJ, Baliga RS, Lumsden NG, et al. Endothelial C-type natriuretic peptide maintains vascular homeostasis. J Clin Invest. 2014; 124: 4039-51, CrossRef.

Atkins GB, Wang Y, Mahabeleshwar GH, Shi H, Gao H, Kawanami D, et al. Hemizygous deficiency of Krüppel-like factor 2 augments experimental atherosclerosis. Circ Res. 2008; 103: 690-3, CrossRef.

Dai G, Vaughn S, Zhang Y, Wang ET, Garcia-Cardena G, Gimbrone MA Jr. Biomechanical forces in atherosclerosis-resistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/Akt-dependent activation of Nrf2. Circ Res. 2007; 101: 723-33, CrossRef.

Hsieh CY, Hsiao HY, Wu WY, Liu CA, Tsai YC, Chao YJ, et al. Regulation of shear-induced nuclear translocation of the Nrf2 transcription factor in endothelial cells. J Biomed Sci. 2009; 16: 12, CrossRef.

Blagovic K, Kim LY, Voldman J. Microfluidic perfusion for regulating diffusible signaling in stem cells. PLoS One. 2011; 6: e22892, CrossRef.

Zakkar M, Van der Heiden K, Luong le A, Chaudhury H, Cuhlmann S, Hamdulay SS, et al. Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arterioscler Thromb Vasc Biol. 2009; 29: 1851-7, CrossRef.

Fledderus JO, Boon RA, Volger OL, Hurttila H, Ylä-Herttuala S, Pannekoek H, et al. KLF2 primes the anti-oxidant transcription factor Nrf2 for activation in endothelial cells. Arterioscler Thromb Vasc Biol. 2008; 28: 1339-46, CrossRef.

Boon RA, Horrevoets AJ. Key transcriptional regulators of the vasoprotective effects of shear stress. Hamostaseologie. 2009; 29: 39-43, CrossRef.

Heo KS, Le NT, Cushman HJ, Giancursio CJ, Chang E, Woo CH, et al. Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J Clin Invest. 2015; 125: 1299-310, CrossRef.

Heo KS, Chang E, Le NT, Cushman H, Yeh ET, Fujiwara K, et al. De-SUMOylation enzyme of sentrin/SUMO-speci c protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res. 2013; 112: 911-23, CrossRef.

Woo CH, Shishido T, McClain C, Lim JH, Li JD, Yang J, et al. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced anti-inflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res. 2008; 102: 538-45, CrossRef.

Liu B, Shuai K. Targeting the PIAS1 SUMO ligase pathway to control inflammation. Trends Pharmacol Sci. 2008; 29: 505-9, CrossRef.

Lerchenmüller C, Heißenberg J, Damilano F, Bezzeridis VJ, Krämer I, Bochaton-Piallat ML, et al. S100A6 regulates endothelial cell cycle progression by attenuating antiproliferative signal transducers and activators of transcription 1 signaling. Arterioscler Thromb Vasc Biol. 2016; 36: 1854-67, CrossRef.

Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2017; 118: 692-702, CrossRef.

Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473: 317-25, CrossRef.

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-33, CrossRef.

Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs pre- dominantly act to decrease target mRNA levels. Nature. 2010; 466: 835-40, CrossRef.

Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006; 20: 515-24, CrossRef.

Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008; 455: 64-71, CrossRef.

Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19: 92-105, CrossRef.

Goedeke L, Rotllan N, Canfrán-Duque A, Aranda JF, Ramírez CM, Araldi E, et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015; 21: 1280-9, CrossRef.

Wagschal A, Naja-Shoushtari SH, Wang L, Goedeke L, Sinha S, deLemos AS, et al. Genome-wide identication of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med. 2015; 21: 1290-7, CrossRef.

Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008; 7: 365-75, CrossRef.

Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem. 2010; 285: 33652-61, CrossRef.

Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA. 2010; 107: 17321-6, CrossRef.

Marquart TJ, Allen RM, Ory DS, Baldán A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA. 2010; 107: 12228-32, CrossRef.

Naja-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010; 328: 1566-9, CrossRef.

Ramirez CM, Dávalos A, Goedeke L, Salerno AG, Warrier N, Cirera-Salinas D, et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol. 2011; 31: 2707-14, CrossRef.

Sun D, Zhang J, Xie J, Wei W, Chen M, Zhao X. MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. FEBS Lett. 2012; 586: 1472-9, CrossRef.

Kim J, Yoon H, Ramírez CM, Lee SM, Hoe HS, Fernández-Hernando C, et al. MiR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression. Exp Neurol. 2012; 235: 476-83, CrossRef.

de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldán Á, Esau C, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013; 112: 1602-12, CrossRef.

Ramírez CM, Goedeke L, Rotllan N, Yoon JH, Cirera-Salinas D, Mattison JA, et al. MicroRNA 33 regulates glucose metabolism. Mol Cell Biol. 2013; 33: 2891-902, CrossRef.

Zhang M, Wu JF, Chen WJ, Tang SL, Mo ZC, Tang YY, et al. MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP- 1 macrophages. Atherosclerosis. 2014; 234: 54-64, CrossRef.

Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res. 2009; 83: 131-9, CrossRef.

Yang K, He YS, Wang XQ, Lu L, Chen QJ, Liu J, et al. MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett. 2011; 585: 854–60, CrossRef.

Tian FJ, An LN, Wang GK, Zhu JQ, Li Q, Zhang YY, et al. Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res. 2014; 103: 100-10, CrossRef.

Chen L, Yang G. Recent advances in circadian rhythms in cardiovascular system. Front Pharmacol. 2015; 6: 71, CrossRef.

Feng D, Lazar MA. Clocks, metabolism, and the epigenome. Mol Cell. 2012; 47: 158-67, CrossRef.

McAlpine CS, Swirsky FK. Circadian influence on metabolism and inflammation in atherosclerosis. Circ Res. 2016; 119: 131-41, CrossRef.

Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat Rev Immunol. 2013; 13: 190-8, CrossRef.

Davidson AJ, London B, Block GD, Menaker M. Cardiovascular tissues contain independent circadian clocks. Clin Exp Hypertens. 2005; 27: 307-11, CrossRef.

McNamara P, Seo SB, Rudic RD, Sehgal A, Chakravarti D, FitzGerald GA. Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell. 2001; 105: 877-89, CrossRef.

Nonaka H, Emoto N, Ikeda K, Fukuya H, Rohman MS, Raharjo SB, et al. Angiotensin II induces circadian gene expression of clock genes in cultured vascular smooth muscle cells. Circulation. 2001; 104: 1746-8, CrossRef.

Rudic RD, McNamara P, Reilly D, Grosser T, Curtis AM, Price TS, et al. Bioinformatic analysis of circadian gene oscillation in mouse aorta. Circulation. 2005; 112: 2716-24, CrossRef.

Lin C, Tang X, Zhu Z, Liao X, Zhao R, Fu W, et al. The rhythmic expression of clock genes attenuated in human plaque-derived vascular smooth muscle cells. Lipids Health Dis. 2014; 13: 14, CrossRef.

Nguyen KD, Fentress SJ, Qiu Y, Yun K, Cox JS, Chawla A. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. Science. 2013; 341: 1483-8, CrossRef.

Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894-7, CrossRef.

Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2: 275-81, CrossRef.

Soehnlein O, Drechsler M, Döring Y, Lievens D, Hartwig H, Kemmerich K, et al. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med. 2013; 5: 471-81, CrossRef.

Viswambharan H, Carvas JM, Antic V, Marecic A, Jud C, Zaugg CE, et al. Mutation of the circadian clock gene Per2 alters vascular endothelial function. Circulation. 2007; 115: 2188-95, CrossRef.

Steffens S, Winter C, Schloss MJ, Hidalgo A, Weber C, Soehnlein O. Circadian control of inflammatory processes in atherosclerosis and its complications. Arterioscler Thromb Vasc Biol. 2017; 37: 1022-8, CrossRef.

Kinlay S, Michel T, Leopold JA. The future of vascular biology and medicine. Circulation. 2016; 13: 2603-9, CrossRef.

Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486: 207-14, CrossRef.

Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124: 4204-11, CrossRef.

Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472: 57-63, CrossRef.

Gregory JC, Buffa JA, Org E, Wang Z, Levison BS, Zhu W, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. 2015; 290: 5647-60, CrossRef.

Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology. 2014; 146: 1564-72, CrossRef.

Garrido AM, Bennett M. Assessment and consequences of cell senescence in atherosclerosis. Curr Opin Lipidol. 2016; 27: 431-8, CrossRef.

Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual Rev Pathol. 2010; 5: 99-118, CrossRef.

Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature. 2011; 479: 547-51, CrossRef.

Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008; 134: 657-67, CrossRef.

Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445: 656-60, CrossRef.

Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med. 2013; 210: 2057-69, CrossRef.

Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008; 133: 1006-18, CrossRef.

Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008; 133: 1019-31, CrossRef.

Coppe JP, Kauser K, Campisi J, Beausejour CM. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem. 2006; 281: 29568-74, CrossRef.

Coppe JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008; 6: e301, CrossRef.

Coppe JP, Rodier F, Patil CK, Freund A, Desprez PY, Campisi J, et al. Tumor suppressor and aging biomarker p16INK4a induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem. 2011; 286: 36396-403, CrossRef.

Okuda K, Khan MY, Skurnick J, Kimura M, Aviv H, Aviv A. Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis. 2000; 152: 391-8, CrossRef.

Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA. 1995; 92: 11190-4, CrossRef.

Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res. 2006; 99: 156-64, CrossRef.

Wang J, Uryga AK, Reinhold J, Figg N, Baker L, Finigan A, et al. Vascular smooth muscle cell senescence & promotes atherosclerosis and features of plaque vulnerability. Circulation. 2015; 132: 1909-19, CrossRef.

Gardner SE, Humphry M, Bennett MR, Clarke MC. Senescent vascular smooth muscle cells drive inflammation through an Interleukin-1alpha-dependent senescence-associated secretory phenotype. Arterioscler Thromb Vasc Biol. 2015; 35: 1963-74, CrossRef.

Aviv H, Khan MY, Skurnick J, Okuda K, Kimura M, Gardner J, et al. Age dependent aneuploidy and telomere length of the human vascular endothelium. Atherosclerosis. 2001; 159: 281-7, CrossRef.

Vasile E, Tomita Y, Brown LF, Kocher O, Dvorak HF. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/ VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J. 2001; 15: 458-66, CrossRef.

Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105: 1541-4, CrossRef.

Rajapakse AG, Yepuri G, Carvas JM, Stein S, Matter CM, Scerri I, et al. Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: inhibition by resveratrol. PLoS One. 2011; 6: e19237, CrossRef.

Yepuri G, Velagapudi S, Xiong Y, Rajapakse AG, Montani JP, Ming X-F, et al. Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging. Aging Cell. 2012; 11: 1005-16, CrossRef.

Wu Z, Yu Y, Liu C, Xiong Y, Montani JP, Yang Z, et al. Role of p38 mitogen-activated protein kinase in vascular endothelial aging: interaction with Arginase-II and S6K1 signaling pathway. Aging. 2015; 7: 70-81, CrossRef.

Gorenne I, Kavurma M, Scott S, Bennett M. Vascular smooth muscle cell senescence in atherosclerosis. Cardiovasc Res. 2006; 72: 9-17, CrossRef.

Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res. 2012; 111: 245-59, CrossRef.

Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014; 15: 482-96, CrossRef.

Childs BG, Baker DJ, Wijshake T, Conopver CA, Campisi J, van Deusen JM. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science. 2016 354: 472-7, CrossRef.

Vaughan DE, Rai R, Khan SS, Eren M, Ghosh AK. Plasminogen activator inhibitor-1 is a marker and a mediator of senescence. Arterioscler Thromb Vasc Biol. 2017; 37: 1446-52, CrossRef.

National Institute of Health [Internet]. The Precision Medicine Initiative Cohort Program – Building a Research Foundationfor 21st Century Medicine. Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director, NIH [updated 2015 Sep 17; cited 2016 Feb 21]. Available from:

pmi/pmi-working-group-report-20150917-2.pdf"> http://www.nih.gov/.

Natarajan P, O’Donnell CJ. Reducing cardiovascular risk using genomic information in the era of precision medicine. Circulation. 2016; 133: 1155-9, CrossRef.

Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154-6, CrossRef.

Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 1987; 84: 6919-23, CrossRef.

Goldstein JL, Basu SK, Brunschede GY, Brown MS. Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell. 1976; 7: 85-95, CrossRef.

Do R, Stitziel NO, Won HH, Jørgensen AB, Duga S, Angelica Merlini P, et al. NHLBI Exome Sequencing Project. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015; 518: 102-6, CrossRef.

Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013; 45: 1274-83, CrossRef.

Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015; 385: 2264-71, CrossRef.

Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, Levy D, Murabito JM, Wang TJ, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004; 291: 2204-11, CrossRef.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302: 1993-2000, CrossRef.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007; 115: 450-8, CrossRef.

Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302: 412-23, CrossRef.

Heller DA, de Faire U, Pedersen NL, Dahlén G, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med. 1993; 328: 1150-6, CrossRef.

Utermann G. The mysteries of lipoprotein(a). Science. 1989; 246: 904-10, CrossRef.

Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361: 2518-28, CrossRef.

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009; 301: 2331-9, CrossRef.

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375: 1536-44, CrossRef.

White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014; 370: 1702-11, CrossRef.

O’Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014; 312: 1006-15, CrossRef.

Nurnberg ST, Zhang H, Hand NJ, Bauer RC, Saleheen D, Reilly MP, et al. From Loci to Biology: Functional Genomics of Genome-Wide Association for Coronary Disease. Circ Res. 2016; 118:586-606, CrossRef.




DOI: https://doi.org/10.18585/inabj.v10i2.479

Indexed by:

                 

                

                

  

 

The Prodia Education and Research Institute